Quarterly ResultMay 7, 2026, 04:41 PM
IN8bio Reports Q1 2026 Results, Positive GBM Data, Equity Plan Approved
AI Summary
IN8bio reported a net loss of $5.1 million for the first quarter ended March 31, 2026, an improvement from $5.6 million in the prior year, with R&D expenses decreasing to $2.6 million. The company announced significant clinical progress, including updated glioblastoma (GBM) data showing a 97% improvement in median progression-free survival and an extended median overall survival compared to standard-of-care. Additionally, stockholders approved the Amended and Restated 2026 Equity Incentive Plan, increasing shares available for issuance by 2,920,000, and elected two Class II directors.
Key Highlights
- Net loss for Q1 2026 was $5.1 million, down from $5.6 million YoY.
- Research and Development expenses decreased to $2.6 million from $3.0 million YoY.
- Cash position was $21.9 million as of March 31, 2026, down from $27.1 million at Dec 31, 2025.
- Stockholders approved the 2026 Equity Incentive Plan, increasing shares available by 2,920,000.
- Glioblastoma (GBM) data showed 97% median progression-free survival improvement (13.0 months vs. 6.6 months SOC).
- GBM median overall survival is 17.2+ months, surpassing 13.2 months for standard-of-care.
- Advancing INB-619 γδ T cell engager platform; initial animal data expected in 2026.
- Updated GBM median overall survival results to be presented at ASCO 2026 on June 1.
Price Impact
More from INAB